SignatureFD’s Rani Therapeutics RANI Stock Holding History

SignatureFD’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-65	Closed	-$1K	–	3291
2021 Q4	$1K	Buy	+65	New	+$1.48K	﹤0.01%	2977

Other funds holding RANI

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ASGS

Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SignatureFD's RANI Position: Q1 2022 in Review

SignatureFD sold out of Rani Therapeutics (RANI) in Q1 2022, closing a stake of 65 shares — an estimated $1K sold.

SignatureFD first reported a position in RANI in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 24 funds tracked by Wall St. Rank hold RANI as of Q1 2022.

SignatureFD reported no remaining Rani Therapeutics position as of Q1 2022 after selling out during the quarter.
SignatureFD sold 65 Rani Therapeutics shares in Q1 2022, an estimated $1K.
SignatureFD first reported a position in Rani Therapeutics in Q4 2021 and held it in 1 quarter.
SignatureFD's Rani Therapeutics position peaked at $1K in Q4 2021.
24 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.